Cancer Family
Epithelial Neoplasm
CI-CAN-00000016Explore in graph →
Non-malignant7,525 active trials118 approved drugs1,152 evidence items
- NCIt
- C3709
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000016Explore in graph →
Clinical trials
26,878 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03610906 | Prospective Pilot Study Identifying Clinically Relevant Biological Targets for Medical Therapy | enrolling by invitation | — | 250 | University of Colorado, DenverOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT07488572 | Safety and Efficacy of Yiwoxidan Anti (AK112) Monotherapy in Patients With Metastatic Renal Clear Cell Carcinoma Who Are Intolerant to TKI Treatment: a Prospective, Single Arm, Phase II Clinical Study | enrolling by invitation | Phase 2 | 60 | Sun Yat-sen UniversityOTHER | 1 |
| Mar 23, 2026 |
| clinicaltrials |
| NCT06650748 | Multigene Risk Score Combined With Ki-67 Dynamic Assessment in Stratified Neoadjuvant Endocrine Therapy Treatment With or Without CDK4/6 Inhibitors in HR+/HER2- Breast Cancer(NeoMARS) | enrolling by invitation | Phase 2 | 100 | Peking UniversityOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT06474091 | Liquid Biopsy MonitORing Of CholangioCarcinOma for Treatment Response and Prognostic Outcomes (MOROCCO) | enrolling by invitation | — | 100 | Mayo ClinicOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT00587314 | The Effect of Ablation Therapy on Barrett's Esophagus(ablation IN BE) | enrolling by invitation | — | 600 | Mayo ClinicOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT06508138 | Clinical Trial Assessing the Safety and Immunologic Correlates of Heterologous Prime-Boost With pNGVL4a-Sig/E7(Detox)/HSP70 and TA-HPV in Healthy Donors Followed by Peripheral Blood Collection(J21112LINKED) | enrolling by invitation | Phase 1 | 24 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT07454941 | Artificial Intelligence-assisted HER2 Expression Assessment in Urothelial Carcinoma Based on Imaging-pathology Omics | enrolling by invitation | — | 4,000 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT06624189 | Active Choice Clinical Decision Support (CDS): Hepatocellular Carcinoma (HCC) Screening in Patients With Cirrhosis | enrolling by invitation | — | 1,300 | NYU Langone HealthOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT05441475 | A Phase 2, Open-Label Study of ABSK-011 Combined Atezolizumab or SOC in HCC Patients | enrolling by invitation | Phase 2 | 118 | Abbisko Therapeutics Co, LtdINDUSTRY | 1 | Feb 25, 2026 | clinicaltrials |
| NCT04996316 | MammoScreen Breast Cancer Risk Assessment and Decision Aid for Breast Cancer Screening and Referrals | enrolling by invitation | — | 1,141 | OHSU Knight Cancer InstituteOTHER | 1 | Feb 13, 2026 | clinicaltrials |
| NCT06730685 | Sarcopenia and Cachexia in Patients With Lung Cancer(PHILUCA) | enrolling by invitation | — | 160 | Zealand University HospitalOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT07401498 | Complications Associated With Lymphadenectomy (LAD) in Surgical Treatment of Non-small Cell Lung Cancer (NSCLC).(LNDNSCLC-RUS) | enrolling by invitation | N/A | 1,000 | Regional Clinical Oncology DispensaryOTHER_GOV | 1 | Feb 10, 2026 | clinicaltrials |
| NCT06250777 | Efficacy and Safety of T-DXd in HER2-mutant Advanced Lung Cancer Patients With Asymptomatic Brain Metastases(ELPIS) | enrolling by invitation | Phase 2 | 27 | Yonsei UniversityOTHER | 1 | Feb 9, 2026 | clinicaltrials |
| NCT07390565 | YSQTG Combined With Immuno-chemotherapy for Extensive-Stage Small Cell Lung Cancer | enrolling by invitation | N/A | 308 | LI FENGOTHER | 1 | Feb 9, 2026 | clinicaltrials |
| NCT06061328 | Project OASIS: Optimizing Approaches to Select Implementation Strategies(OASIS) | enrolling by invitation | N/A | 8,020 | VA Office of Research and DevelopmentFED | 1 | Feb 4, 2026 | clinicaltrials |
| NCT07373951 | Retrospective Multicenter Study of Patient-level T1CE/FLAIR MRI Deep Learning to Predict EGFR/ALK Driver Status in NSCLC Brain Metastases With External Validation and Survival Analysis(DL-DriverBM) | enrolling by invitation | — | 380 | Ming YangOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT07376629 | A Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBC | enrolling by invitation | Phase 2 | 60 | Huabo Biopharm Co., Ltd.INDUSTRY | 1 | Jan 29, 2026 | clinicaltrials |
| NCT06370416 | the Prevention of Bone Marrow Suppression Caused by Chemotherapy in Advanced NSCLC With Trilaciclib | enrolling by invitation | Phase 2 | 41 | Henan Cancer HospitalOTHER_GOV | 1 | Jan 28, 2026 | clinicaltrials |
| NCT02081755 | Safety and Efficacy of Everolimus Treatment in Liver Transplantation for Liver Cancer | enrolling by invitation | Phase 4 | 336 | Baylor Research InstituteOTHER | 1 | Jan 27, 2026 | clinicaltrials |
| NCT07356466 | Clinical Efficacy of Pucotenlimab Combined With Lenvatinib and SOX Versus SOX Alone in Patients With HER2-Negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma(FUGES032) | enrolling by invitation | Early Phase 1 | 100 | Fujian Medical UniversityOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT07347392 | The Role of Radiotherapy for the Management of Non-melanoma Skin Cancer in Denmark.(DOSCA-2) | enrolling by invitation | — | 2,900 | University of AarhusOTHER | 1 | Jan 16, 2026 | clinicaltrials |
| NCT07334587 | Comparison of Efficacy and Safety Between FOLFOX-6 and CAPOX in Metastatic Colorectal Carcinoma | enrolling by invitation | N/A | 248 | Allama Iqbal Medical CollegeOTHER | 1 | Jan 12, 2026 | clinicaltrials |
| NCT05570994 | 177Lu-HTK03170 in mCRPC With PSMA Positive Disease | enrolling by invitation | Phase 1 / Phase 2 | 50 | British Columbia Cancer AgencyOTHER | 1 | Jan 8, 2026 | clinicaltrials |
| NCT07316361 | GYNORYLAQ™-VLINIVAL™: Ψ-Guided Personalized Neoantigen Peptide Vaccine for High-Risk Endometrial Cancer(GYNORYLAQ™) | enrolling by invitation | Early Phase 1 | 40 | Biogenea Pharmaceuticals Ltd.INDUSTRY | 1 | Jan 7, 2026 | clinicaltrials |
| NCT07311070 | Treatment of Basal Cell Carcinoma (BCC) of the Skin, of the Morpheiform, Infiltrative, and Noduloulcerative Types in Inoperable Patients and Not Suitable for Radiotherapy Using Formulated Methylene Blue | enrolling by invitation | Phase 3 | 20 | Daryoush Hamidi Alamdari, PhDOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT07312578 | Nimotuzumab,Camrelizumab, and Neoadjuvant Chemotherapy（nCT） in the Treatment of Esophageal Squamous Cell Carcinoma | enrolling by invitation | Phase 2 | 48 | Peking UniversityOTHER | 1 | Dec 31, 2025 | clinicaltrials |
| NCT06462521 | Cold Snare Piecemeal Resection vs Cold Snare Endoscopic Mucosal Resection(CARDINAL) | enrolling by invitation | N/A | 570 | Indiana UniversityOTHER | 1 | Dec 30, 2025 | clinicaltrials |
| NCT01385722 | Molecular Analysis of Thoracic Malignancies | enrolling by invitation | — | 1,000 | Stanford UniversityOTHER | 1 | Dec 26, 2025 | clinicaltrials |
| NCT07301983 | Evaluation of Lymph Node Analysis Using One Step Nucleic Acid Amplification (OSNA) in Patients With Lung Cancer Who Underwent Robotic Lung Resection, Comparison With Traditional Methods(LALC) | enrolling by invitation | — | 130 | Azienda Ospedaliero, Universitaria PisanaOTHER | 1 | Dec 24, 2025 | clinicaltrials |
| NCT07290764 | Survival Analysis of Surgical Resection Versus Observation in Patients With Initially uHCC Achieving CR After Systemic Therapy | enrolling by invitation | — | 729 | Fujian Provincial HospitalOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT04945317 | ROSE for Improved Molecular Marker Testing Via EBUS(ROSE/NoROSE) | enrolling by invitation | N/A | 349 | Johns Hopkins UniversityOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT07285434 | Clinical Study of the Therapeutic Effectiveness of In-silico-Designed, Machine Learning Inspired, and Quantum-molecularly Coupled Personalized Neoantigenic Vaccines Microlyvaq™ in Patients With Advanced Non-small Cell Lung Cancer(Microlyvaq™) | enrolling by invitation | Early Phase 1 | 90 | Biogenea Pharmaceuticals Ltd.INDUSTRY | 1 | Dec 16, 2025 | clinicaltrials |
| NCT06843681 | Trastuzumab Plus Taxane Neoadjuvant Therapy for HER2-Positive Breast Ductal Carcinoma In Situ (DCIS) : A Phase II Study | enrolling by invitation | Phase 2 | 54 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Nov 28, 2025 | clinicaltrials |
| NCT07241676 | Early Recurrence After Surgery for Pancreatic Cancer(POCEMON BLUE) | enrolling by invitation | — | 500 | Azienda Ospedaliera di PadovaOTHER | 1 | Nov 21, 2025 | clinicaltrials |
| NCT02270567 | RegisterNET - A Registry for Neuroendocrine Tumors in the USA and Worldwide(RegisterNET) | enrolling by invitation | — | 400 | Wren Laboratories LLCINDUSTRY | 1 | Nov 13, 2025 | clinicaltrials |
| NCT04539717 | FAST (Focused Abbreviated Screening Technique)-MRI Study | enrolling by invitation | — | 820 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Oct 8, 2025 | clinicaltrials |
| NCT06882876 | JS014 Combined With Toripalimab and TACE in Unresectable HCC: a Phase Ib Study | enrolling by invitation | Phase 1 | 20 | Xiangya Hospital of Central South UniversityOTHER | 1 | Sep 19, 2025 | clinicaltrials |
| NCT07101900 | 68Ga-NYM096 PET/ CT for the Detection of Clear Cell Renal Cell Carcinoma in Presurgical Patients With Renal Masses | enrolling by invitation | Phase 2 | 100 | Peking Union Medical College HospitalOTHER | 1 | Aug 8, 2025 | clinicaltrials |
| NCT07072676 | The Use of Assistive Gait Devices Can Reduce the Risk of Falls in Patients With Neuromuscular Diseases Following a Training Period.(Risk of fall) | enrolling by invitation | N/A | 30 | LMU KlinikumOTHER | 1 | Jul 18, 2025 | clinicaltrials |
| NCT07052448 | The Efficacy of Sequential RT After Triple Therapy for uHCC | enrolling by invitation | — | 35 | Fujian Provincial HospitalOTHER | 1 | Jul 4, 2025 | clinicaltrials |
| NCT07046832 | Clinical Evaluation of an Augmented Reality Intraprocedural Needle Guidance Platform for Soft Tissue Biopsy | enrolling by invitation | N/A | 104 | MediView XR, Inc.INDUSTRY | 1 | Jul 2, 2025 | clinicaltrials |
| NCT07047937 | Explainable Machine Learning for Predicting Early Gastric Cancer | enrolling by invitation | — | 10 | Wenzhou Central HospitalOTHER | 1 | Jul 2, 2025 | clinicaltrials |
| NCT07034859 | Cabergoline in the Management of Nonfunctioning Pituitary Adenoma | enrolling by invitation | Phase 4 | 30 | National Taiwan University HospitalOTHER | 1 | Jun 24, 2025 | clinicaltrials |
| NCT07023848 | PET Image Exploration of 89Zr-labeled Antibody Fragments Targeting HER2 in Patients With Malignant Tumors | enrolling by invitation | Early Phase 1 | 10 | Affiliated Hospital of Jiangnan UniversityOTHER | 1 | Jun 17, 2025 | clinicaltrials |
| NCT07023861 | The Exploration of Novel Radionuclide-labeled HER2-targeting Antibodies in the Diagnosis of HER2-positive Malignancies | enrolling by invitation | Early Phase 1 | 20 | Affiliated Hospital of Jiangnan UniversityOTHER | 1 | Jun 17, 2025 | clinicaltrials |
| NCT07016737 | Immunochemotherapy ± Salvage Chemoradiation for Local Recurrence of Esophageal Squamous Cell Carcinoma After Definitive Chemoradiotherapy(ESO-Nanjing12) | enrolling by invitation | Phase 3 | 79 | Ye jinjunOTHER | 1 | Jun 12, 2025 | clinicaltrials |
| NCT06997458 | Liquid BiOpsy, Lung and Colon Cancer in AndaluciA(LOLA-PROJECT) | enrolling by invitation | — | 500 | Fundación Pública Andaluza para la Investigación Biomédica Andalucía OrientalOTHER | 1 | May 30, 2025 | clinicaltrials |
| NCT06990178 | Adaptive Neoadjuvant Therapy for Esophageal Cancer | enrolling by invitation | N/A | 43 | Cancer Hospital Chinese Academy of Medical Science, Shenzhen CenterOTHER | 1 | May 25, 2025 | clinicaltrials |
| NCT06419179 | Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC)(GUIDANCE) | enrolling by invitation | Phase 2 | 29 | University of CologneOTHER | 1 | May 20, 2025 | clinicaltrials |
| NCT06967662 | Selective Plasma Adsorption of Extracellular DNA in Prevention of Intraoperative Metastasis in Pancreatic Cancer (Pilot Study)(INTRACOR_pilot) | enrolling by invitation | N/A | 28 | Ilyinskaya Hospital, JSCOTHER | 1 | May 16, 2025 | clinicaltrials |
Data updated 22 days agoSource updated Mar 23, 2026source: clinicaltrials